Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study
Autor: | Ilse Andrea Moreno-Arquieta, Cassandra Michele Skinner-Taylor, Jorge A. Esquivel-Valerio, Patricia Ludivina Gonzalez-Garcia, Fatima Del Rocio Almaraz-Juarez, Gisela García-Arellano, Dioncio Angel Galarza-Delgado, Jesus Alberto Cardenas-de la Garza |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
medicine.medical_specialty COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) Cross-sectional study Immunology Population Observational Research Drug-related side effects and adverse reactions Rheumatology Internal medicine Rheumatic Diseases Surveys and Questionnaires medicine Immunology and Allergy Humans In patient Adverse effect education Mexico Pandemics Vaccine hesitancy education.field_of_study business.industry SARS-CoV-2 Vaccination COVID-19 Autoimmune rheumatic diseases Middle Aged Vaccine efficacy Cross-Sectional Studies Female business |
Zdroj: | Rheumatology International |
ISSN: | 1437-160X |
Popis: | Data regarding COVID-19 vaccine efficacy and adverse events (AE) in patients with autoimmune and inflammatory rheumatic diseases (AIIRD) have been published recently although these mostly include the mRNA vaccines (Pfizer-BioNTech and Moderna) and the ChAdOx1 nCoV-19/AZD1222 (Oxford-AstraZeneca). This research aimed to study the prevalence of AE presented with six different SARS-CoV-2 vaccines {ChadOX1 nCoV-19 (AZD1222), Ad5-nCoV2, Ad26.COV2.S, mRNA-1273, BNT162b2, and CoronaVac} in Mexican patients with AIIRD. We performed a cross-sectional study about vaccine history. Two hundred and twenty five consecutive patients were recruited, mean age was 50.7 years and the majority (n = 213; 94.6%) were females. One hundred and seven (47.5%) received BNT162b2 mRNA, 34 (15.1%) Ad5-nCoV, 29 (12.8%) mRNA-1273, 28 (12.4%) ChAdOX1 nCoV-19 (AZD1222), 22 (9.7%) CoronaVac and 5 (2.2%) Ad26.COV2.S. The vaccines that had the most AE proportionally to the number of patients vaccinated were Janssen (5; 100%) followed by Pfizer-BioNTEch (86; 80%) and CanSinoBIO (27; 79.4%). Localized pain was the most frequent (158; 70.2%) AE. Fatigue (78; 34.7%), headache (69; 30.6%) and muscle ache (66; 29.3%) were the most common systemic symptoms. No serious AE that required medical attention or hospitalization were reported. The current results support the safety of different COVID-19 vaccines in patients with AIIRD. This information can help fight vaccine hesitancy in this population. |
Databáze: | OpenAIRE |
Externí odkaz: |